WO2006015774A1 - Composition physiologiquement acceptable contenant de l'acide alpha-lipoique, de la creatine et un phospholipide - Google Patents

Composition physiologiquement acceptable contenant de l'acide alpha-lipoique, de la creatine et un phospholipide Download PDF

Info

Publication number
WO2006015774A1
WO2006015774A1 PCT/EP2005/008375 EP2005008375W WO2006015774A1 WO 2006015774 A1 WO2006015774 A1 WO 2006015774A1 EP 2005008375 W EP2005008375 W EP 2005008375W WO 2006015774 A1 WO2006015774 A1 WO 2006015774A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition according
creatine
treatment
agent
preparation
Prior art date
Application number
PCT/EP2005/008375
Other languages
German (de)
English (en)
Inventor
Hans Schuhbauer
Ralf JÄGER
Martin Purpura
Original Assignee
Bioghurt Biogarde Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioghurt Biogarde Gmbh & Co. Kg filed Critical Bioghurt Biogarde Gmbh & Co. Kg
Publication of WO2006015774A1 publication Critical patent/WO2006015774A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • composition containing alpha lipoic acid, creatine and a phospholipid
  • the present invention describes a novel physiologically acceptable composition and its use.
  • ⁇ -lipoic acid (thioctic acid, l, 2-dithiolane-3-pentanoic acid) has been known for about 50 years as a growth factor from microorganisms; however, it also occurs as an R - (+) - enantiomer in low concentrations in higher plants and animals.
  • Alpha-lipoic acid acts physiologically in hydrophilic and lipophilic media as coenzyme of the oxidative decarboxylation of ⁇ -ketocarboxylic acids (eg pyruvate, ⁇ -ketoglutarate).
  • ⁇ -lipoic acid is also involved in the degradation of certain amino acids as a cofactor.
  • ⁇ -lipoic acid and its associated redox partner dihydrolipoic acid have strongly antioxidative and sometimes also pro-oxidative properties, which is why ⁇ -lipoic acid is also referred to as a "universal antioxidant.”
  • ⁇ -lipoic acid is also referred to as a "universal antioxidant.”
  • racemic ⁇ -lipoic acid comes both as a pure solid in admixture with other components , in solid galenic formulations but also in infusion solutions for use.
  • Creatine naturally abundant in meat, fish or breast milk, is crucial for muscle movement, metabolism and energy balance, and is therefore of similar importance as proteins, fats, carbohydrates, vitamins or minerals. More than 95% of the body's total creatine is in skeletal muscle tissue; but creatine is also detectable in the heart or brain. The endergonic phosphorylation of creatine in the mitochondria of the cells leads to a very high-energy compound Phosphocreatine, which as a buffer increases the amount of readily available energy (as ATP derived from ADP in the cytosol). Because it boosts the muscle's ability to absorb sugar, the creatine built up or taken up in muscle also enhances the hypoglycemic effect of insulin.
  • creatine in the liver and kidney is formed enzymatically from the amino acids glycine, arginine and methionine (as S-adenosyl-methionine); however, more than 50% of their own needs must be met by creatine intake via the diet or as a food supplement.
  • Phospholipids are important building blocks of cell membranes. Their amphiphilic character, which enables them to form the lipid bilayer of the cell walls, is due to the combination of a hydrophilic head group (a phosphate ester group at the central glycerol moiety) with a lipophilic long carbon chain chain of fatty acids. Ethern or sphingosinen lipidkerte formed. In addition to the structural function, many phospholipids also fulfill central metabolic functions, such as key molecules for signal transduction mechanisms, membrane fusions or membrane anchors for proteins.
  • hydrophilic head group a phosphate ester group at the central glycerol moiety
  • Ethern or sphingosinen lipidkerte formed.
  • many phospholipids also fulfill central metabolic functions, such as key molecules for signal transduction mechanisms, membrane fusions or membrane anchors for proteins.
  • phospholipid fractions are used in the pharmaceutical industry primarily as surface-active substances since they can be used as emulsion or dispersion formers, as solubilizers or dissolution accelerators and as plasticizers. Accordingly, there are a number of applications in skin creams, ointments, aerosols and suppositories, in galenic forms of retardation as well as in parenteral or enteral nutrition.
  • Phosphatidylserine (PS) is a low-abundant natural constituent of soya lecithin and is produced enzymatically.
  • PS performs various structural and regulatory functions, including the stabilization of cell membranes, the repair of old or damaged cells, the absorption of calcium into the cell, the release of the messenger acetylcholine, and the activation of cell membrane-bound proteins (eg protein kinase C, ATPase, tyrosine hydroxylase).
  • Phosphatidylcholine (PC) is an essential component of the life and functioning of all human cells, especially liver cells. Racemic ⁇ -lipoic acid is approved for the treatment of liver diseases and neuropathies (eg diabetic polyneuropathy); their use as an effective inhibitor of the replication of HTV-1 viruses has been discussed (see Klin. Klischr., 1991, 69 (15), 722-724).
  • WO 99/51097 describes the combination of creatine, creatine phosphate or creatine analogs with a neuroprotective agent such as lipoic acid for the treatment of nervous system disorders.
  • WO 96/14063 A1 describes the sole use of creatine, creatine phosphate or creatine analogues for the treatment of such disorders of the nervous system.
  • a study on the use of lipoic acid as a co-medication for patients with dementia of the Alzheimer's type can be found in Arch. Gerontol Geriatr. 2001, 32 (3), 275-282.
  • WO 00/61537 A1 teaches the synthesis of lipoic acid-containing formulations and their use in the treatment of oxidative stress and endothelial dysfunction without creatine and / or phospholipids being included in the corresponding formulations.
  • WO 01/32168 A1 combines L-carnitine with a physiologically active antioxidant (including lipoic acid) for the treatment of mild forgetfulness.
  • Annais of the New York Academy of Sciences 1994, 717, 122-8 describes the beneficial effect of lipoic acid on the perception of rodents, and according to Pharmacol. Biochem. Behav.1993, 46 (4), 799-805, lipoic acid delivery improves the memory of mice.
  • lipoic acid delivery improves the memory of mice.
  • WO 00/53176 Al describes the use of novel pharmaceutical, dietary or cosmetic formulations based on lipoic acid and cysteine and their use in compensating for changes in the anaerobic and aerobic energy balance and in the treatment of complications due to oxidative stress. According to J. Rev. Medico-chirurgic. Malad. Foie 1966, 41 (1), 7-18 was able to treat acute liver atrophy with a formulation containing lipoic acid and coenzyme A. In FASEB J.
  • racemic or enantiomerically pure ⁇ -lipoic acid to light and temperature and a general tendency to polymerize is known to be a considerable disadvantage.
  • a combination with creatine analogues and phospholipids in the context of the present invention surprisingly results in a considerable stabilization of ⁇ -lipoic acid towards light- or temperature-induced decomposition or polymerization.
  • racemic or enantiomerically pure dihydrolipoic acid is resistant to polymerization under normal conditions of use, it has a high affinity for oxygen or other mild or strong oxidizing agents.
  • lipoic acid component (a) come for the claimed composition according to the invention, in particular racemic ⁇ -lipoic acid, enantiomerically pure R-
  • the ⁇ -lipoic acid or dihydrolipoic acid may also be wholly or partly in the form of their salts.
  • creatine component (b) have compounds from the
  • 1: 1 to 5 1, preferably 1: 1 to 3: 1, creatine ⁇ -ketoglutarate, creatine pyruvate, creatine phosphate, creatine acetate, creatine folate, creatine dihydrolipoate, creatine lipoate, creatinol, their salts and derivatives such as e.g. Creatine ester proved.
  • phospholipid component (c) are compounds from the class of phosphatidic acids, glycerol phospholipids (glycerol phosphatides),
  • Sphingophospholipids or plasmalogens are preferred, with phosphatidylserine (PS), phosphatidylcholine (PC), phosphatidylethanolamine (PE), cardiolipin, 3-phosphatidylglycerol (PG), 3-phosphatidylglycerol-1-P or phosphatidylinositol (PI) being considered particularly suitable.
  • PS phosphatidylserine
  • PC phosphatidylcholine
  • PE phosphatidylethanolamine
  • cardiolipin 3-phosphatidylglycerol
  • PG 3-phosphatidylglycerol
  • PI phosphatidylinositol
  • the lipoic acid component (a) should in proportions of 0.01 to 80 wt .-%, preferably in proportions of 0.1 to 50.0 wt .-% and particularly preferably in proportions of 1.0 to 25.0 wt .-%, in each case based on the total weight of the components (a), (b) and (c) in the composition. All parts by weight given here with respect to component (a) are racemic or optically pure ⁇ -lipoic acid. This means that when using lipoic acid derivatives or salts, the stated amounts of dosages correspond to those of the free lipoic acid, and thus have to be adapted to the changed molecular weight.
  • the creatine component (b) should be present in proportions of I 5 O to 99.9% by weight, preferably in proportions of 5.0 to 99.0% by weight and more preferably in fractions of 25.0 to 90, 0% by weight, again in each case based on the total weight of components (a), (b) and (c) in the composition. All parts by weight given in relation to component (b) are based on pure creatine, which means that when creatine monohydrate or creatine salts are used, the stated amounts of the dosages correspond to those of free creatine and must therefore be adapted to the changed molecular weight.
  • the phospholipid component (c) should be present in proportions of from 0.01 to 80.0% by weight, preferably in proportions of from 0.1 to 50.0% by weight and more preferably in fractions of from 1.0 to 25, 0 wt .-%, in each case based on the total weight of components (a), (b) and (c) are used in the composition, wherein stated weight proportions with respect to component (c) directly to the respective used phospholipid or mixture of phospholipids Respectively.
  • auxiliaries such as binders (eg ethylcellulose, hydroxyethylcellulose, carboxymethylcellulose, starch, gelatin, polyglycols, polyacrylates, polyvinylpyrrolidone, polyvinyl alcohols and their copolymers, alginates, sucrose, glucose or polysaccharides such as pectin, gum arabic , Guar gum), fillers (such as cellulose or cellulose derivatives, glucose, fructose, sucrose, calcium phosphates, calcium sulfates, calcium carbonates, starch or modified starch, mannitol or sorbitol), disintegrants (such as cellulose or cellulose derivatives, alginates, starch or modified starch), wetting agents (such as sodium salts of aliphatic sulfonic acids such as sodium lauryl sulfate, sodium diocryl sulfosuccinate or polysorbates), flow aids (such as colloidal silica,
  • binders eg
  • composition according to the invention can preferably be administered in medicaments, as nutritional supplements, foods, drinks and / or in cosmetics, in particular by means of peroral, dermal, parenteral, enteral, rectal, vaginal or topical application.
  • peroral, dermal, parenteral, enteral, rectal, vaginal or topical application in particular by means of peroral, dermal, parenteral, enteral, rectal, vaginal or topical application.
  • Composition can i.a. in gels, semi-solid formulations or solid
  • the administration of the composition according to the invention is ideally carried out in a single dose between 10 mg and 10 g, preferably between 0.5 and 5.0 g.
  • the daily dose of the composition according to the invention should be between 30 mg and 50 g, preferably between 1.0 and 20 g.
  • the proportion of the three components (a), (b) and (c) of the composition according to the invention can be varied within the specified limits.
  • arteriosclerotic or vasodilatory effects as well as circulatory disorders can be determined with the aid of flow-mediated progression (flow-induced dilation, FMD).
  • flow-mediated progression flow-induced dilation, FMD.
  • Extensive measurement methods are available for determining the blood glucose value (eg oral glucose tolerance test, OGTT), hyperlipoproteinemia (eg lipoprotein electrophoresis with subsequent ultracentrifugation) as well as insulin sensitivity and insulin resistance (eg insulin glucose tolerance test, IGTT).
  • oxidative stress for example, the effect of reactive oxygen and nitrogen compounds on redox-active enzymes by means of enzyme kinetic and structural analysis of body-own proteins can be used.
  • the content of cardiolipin as a parameter is suitable (compare, for example, Neurochem., 1994, 25, 295-300).
  • the damaging extent of photodermatoses can be categorized by comparative observations, identification of the skin flora, and determination of relative skin hydration.
  • Alzheimer's disease the fourth leading cause of death in industrialized countries (5 - 20% of 65 to 80 year olds are affected) - is a diagnosis of living people after the onset of typical symptoms (initially memory disorders, later increasingly restlessness Forgetfulness, poor concentration, spatial disturbances), on the other hand, can only be achieved by excluding similar diseases. A definitive diagnosis can only be made post-mortem. In neurological examination, extrapyrimidal syndromes or pyramidal tract signs occur in rare cases.
  • the present invention also generally includes the ability to use the claimed composition to produce an agent that is suitable for slowing down degenerative and, in particular, progressive brain changes. Alternatively or additionally, the use for the preparation of an agent for the treatment and alleviation of complications and symptoms associated with schizophrenia, dementia, organic psychosis or cognitive dissonance in question.
  • the present invention provides the possibility of the composition for the preparation of an agent for the treatment of dementia infantilis, phenylketonuria, Alzheimer's Disease, Huntington's disease (Huntington's disease), epilepsy, Pick's disease, Binswanger's disease, Friedreich's ataxia, ParMnson's syndrome, Down syndrome, HIV disease, or Creutzfeldt-Jakob disease, or for the preparation of an agent for treatment of metabolic or degenerative diseases of the cerebral nerve tissue, in particular for the treatment of cerebral atrophy and brain-localized atrophy due to local circulatory disorders.
  • the present invention contemplates the preparation of an agent for the treatment of complications associated with atherosclerosis, an agent for treating complications associated with endothelial dysfunction, an agent for the treatment of complications associated with oxidative stress, an agent for the treatment of Complications associated with impaired lipid metabolism, as well as the production of a scar tissue treatment agent.
  • compositions for the preparation of an agent used before, during and after radiotherapy or X-ray examination as well as for the treatment of effects caused by ionizing radiation or for the preparation of an agent for treating symptoms in the body
  • somatogenic, endogenous, psychogenic or pharmacogenic depression for the preparation of an agent for the improvement of cognitive functions and for the treatment of mental or memory disorders and as anorectic.
  • compositions for the preparation of an agent for the treatment of dystrophies and mitochondrial, metabolic or endocrine myopathies in particular Duchenne-type x-linked recessive dystrophies and myotonic dystrophies (Curschmann-Steinert-Batten syndrome), hyperthyroidism, Hypothyroidism and Cushing syndrome I as well as mitochondrial encephalomyopathies, as well as the use for the preparation of an agent for the prevention or support of therapeutic measures during healing, convalescence, remission, regeneration or rehabilitation after open or closed grade 1 to 4 fractures Framework of reduction, retention, immobilization, occupational therapy or physiotherapy.
  • Example 1 500 mg gelatin capsules each containing: ( ⁇ ) - ⁇ -lipoic acid 60 mg
  • gelatine capsules are used to increase brain function and, in particular, memory performance, administered orally three times a day.
  • the daily dose of the dosage form is 1.5 g.
  • Example Z Gelatin capsules with a sustained action of 500 mg each, containing: ( ⁇ ) -dihydrolipoic acid 50 mg
  • gelatin capsules for invigorating and even memory enhancement are administered orally twice a day.
  • Dosage form is 0.8 g.
  • the effervescent powder is dissolved in 2 g portions in water or stirred into yogurt and absorbed orally.
  • gelatin capsules are administered orally three times a day.
  • the daily dose of the dosage form is 1.2 g.
  • the daily dose of the dosage form is 2.4 g.
  • Example 6 400 mg gelatin capsules containing:
  • Excipients 100 mg These gelatin capsules are administered orally four times a day.
  • the daily dose of the dosage form is 1.6 g.
  • the data from respective applications of the dosage forms according to the invention on isolated cells, animals and humans show an overall reduced formation of reactive oxygen particles, reduced oxidative stress and reduced aging effects such as e.g. increased muscular activity, delayed fatigue or increased activity.
  • reduced oxidative stress e.g. increased muscular activity, delayed fatigue or increased activity.
  • affectivity such as a positive mood of grandeur, the elimination of joylessness, passivity and inferiority, reduction of irritability, hypersensitivity and grief reactions.
  • this is often accompanied by a reduction in appetite, a reduction in the amount of food consumed and a reduction in weight.
  • Flow-mediated dilatation also has positive effects after administration of the pharmaceutical dosage forms according to the invention described in the examples.
  • Hypolipoproteinemias, hypercholesterolemias and lipidoses are significantly reduced.
  • the wound closure of wounded or destroyed tissue and the regeneration of granulation or scar tissue in the course of wound healing are significantly accelerated, especially in the reparative phase.

Abstract

L'invention concerne une nouvelle composition physiologiquement acceptable qui contient essentiellement de l'acide a-lipoïque, de la créatine, ainsi qu'un phospholipide et/ou un de ses dérivés appropriés. Cette composition contient, de préférence, 0,01 à 80 % en poids du constituant acide lipoïque, 1,0 à 99,9 % en poids du constituant créatine et 0,01 à 80 % en poids du constituant phospholipide. Elle est principalement utilisée pour ralentir les modifications dégénératives et notamment progressives du cerveau. Des formes galéniques, telles que compléments alimentaires, aliments, boissons, médicaments, produits cosmétiques, se sont avérées particulièrement appropriées. En général, la composition selon l'invention est utilisée en doses individuelles comprenant entre 10 mg et 10 g. La combinaison selon l'invention permet d'obtenir des résultats thérapeutiques qui dépassent les effets cumulés des composés individuels et qui représentent des cas d'application qui n'étaient pas connus jusqu'à maintenant pour les composés individuels.
PCT/EP2005/008375 2004-08-06 2005-08-02 Composition physiologiquement acceptable contenant de l'acide alpha-lipoique, de la creatine et un phospholipide WO2006015774A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004038155.0 2004-08-06
DE102004038155A DE102004038155A1 (de) 2004-08-06 2004-08-06 Physiologisch verträgliche Zusammensetzung enthaltend alpha-Liponsäure, Kreatin und ein Phospholipid

Publications (1)

Publication Number Publication Date
WO2006015774A1 true WO2006015774A1 (fr) 2006-02-16

Family

ID=35311552

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/008375 WO2006015774A1 (fr) 2004-08-06 2005-08-02 Composition physiologiquement acceptable contenant de l'acide alpha-lipoique, de la creatine et un phospholipide

Country Status (2)

Country Link
DE (1) DE102004038155A1 (fr)
WO (1) WO2006015774A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007096164A2 (fr) * 2006-02-23 2007-08-30 Merz Pharma Gmbh & Co. Kgaa Créatine pour le traitement des dyskinésies induites par l-dopa
JP2007308468A (ja) * 2006-05-18 2007-11-29 Bhn Kk 基礎代謝増強剤
WO2008137137A1 (fr) * 2007-05-03 2008-11-13 Avicena Group, Inc. Dérivés ascorbyle de la créatine et procédés d'utilisation de ces derniers
WO2008146085A2 (fr) * 2006-06-28 2008-12-04 Gary Viole Composition pour la réduction du stress oxydatif et de l'inflammation par application topique ou administration par voie orale
EP2023718A2 (fr) * 2006-05-11 2009-02-18 Avicena Group, Inc. Composés de ligand de créatine et procédés d'utilisation correspondants
WO2009083169A1 (fr) * 2007-12-21 2009-07-09 Alzchem Trostberg Gmbh Préparation comprenant un composant de créatine, procédé pour sa fabrication, et son utilisation
EP2468272A1 (fr) * 2006-05-11 2012-06-27 Avicena Group, Inc. Procédés de traitement d'un trouble neurologique avec monohydrate de créatine
US20150190410A1 (en) * 2012-07-16 2015-07-09 Dignity Health Use of creatine and phosphocreatine in the treatment of epilepsy and alcohol addiction

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010041187A1 (en) * 1998-10-20 2001-11-15 Carl W Hastings Performance-enhancing dietary supplement
WO2002096218A2 (fr) * 2001-05-28 2002-12-05 Basf Aktiengesellschaft Combinaison d'acides lipoiques, de carnitines et de creatines dans des aliments et des medicaments
WO2003030914A1 (fr) * 2001-10-05 2003-04-17 Bioghurt Biogarde Gmbh & Co. Kg. Utilisation de phosphatidylserine pour traiter le syndrome d'hyperactivite avec deficit d'attention (adhs)
WO2003082182A2 (fr) * 2002-03-28 2003-10-09 Beiersdorf Ag Gels et emulsions phospholipidiques cosmetiques ou pharmaceutiques reticulees a base d'emulsifiants contenant des oxydes d'ethylene ou de propylene
WO2005006890A2 (fr) * 2003-07-10 2005-01-27 Forest Carl A Aliments, boissons, condiments, epices et sauces pour salades a complements specialises
WO2005046705A1 (fr) * 2003-11-12 2005-05-26 Bioghurt Biogarde Gmbh & Co. Kg Utilisation de dreche de distillerie fermentee pour prevenir et/ou traiter des taux augmentes de glycemie

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010041187A1 (en) * 1998-10-20 2001-11-15 Carl W Hastings Performance-enhancing dietary supplement
WO2002096218A2 (fr) * 2001-05-28 2002-12-05 Basf Aktiengesellschaft Combinaison d'acides lipoiques, de carnitines et de creatines dans des aliments et des medicaments
WO2003030914A1 (fr) * 2001-10-05 2003-04-17 Bioghurt Biogarde Gmbh & Co. Kg. Utilisation de phosphatidylserine pour traiter le syndrome d'hyperactivite avec deficit d'attention (adhs)
WO2003082182A2 (fr) * 2002-03-28 2003-10-09 Beiersdorf Ag Gels et emulsions phospholipidiques cosmetiques ou pharmaceutiques reticulees a base d'emulsifiants contenant des oxydes d'ethylene ou de propylene
WO2005006890A2 (fr) * 2003-07-10 2005-01-27 Forest Carl A Aliments, boissons, condiments, epices et sauces pour salades a complements specialises
WO2005046705A1 (fr) * 2003-11-12 2005-05-26 Bioghurt Biogarde Gmbh & Co. Kg Utilisation de dreche de distillerie fermentee pour prevenir et/ou traiter des taux augmentes de glycemie

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007096164A2 (fr) * 2006-02-23 2007-08-30 Merz Pharma Gmbh & Co. Kgaa Créatine pour le traitement des dyskinésies induites par l-dopa
WO2007096164A3 (fr) * 2006-02-23 2007-11-08 Merz Pharma Gmbh & Co Kgaa Créatine pour le traitement des dyskinésies induites par l-dopa
EP2023718A2 (fr) * 2006-05-11 2009-02-18 Avicena Group, Inc. Composés de ligand de créatine et procédés d'utilisation correspondants
EP2023718A4 (fr) * 2006-05-11 2010-04-21 Avicena Group Inc Composés de ligand de créatine et procédés d'utilisation correspondants
EP2468272A1 (fr) * 2006-05-11 2012-06-27 Avicena Group, Inc. Procédés de traitement d'un trouble neurologique avec monohydrate de créatine
JP2007308468A (ja) * 2006-05-18 2007-11-29 Bhn Kk 基礎代謝増強剤
WO2008146085A2 (fr) * 2006-06-28 2008-12-04 Gary Viole Composition pour la réduction du stress oxydatif et de l'inflammation par application topique ou administration par voie orale
WO2008146085A3 (fr) * 2006-06-28 2009-01-29 Gary Viole Composition pour la réduction du stress oxydatif et de l'inflammation par application topique ou administration par voie orale
WO2008137137A1 (fr) * 2007-05-03 2008-11-13 Avicena Group, Inc. Dérivés ascorbyle de la créatine et procédés d'utilisation de ces derniers
WO2009083169A1 (fr) * 2007-12-21 2009-07-09 Alzchem Trostberg Gmbh Préparation comprenant un composant de créatine, procédé pour sa fabrication, et son utilisation
US8506989B2 (en) 2007-12-21 2013-08-13 Alzchem Trostberg Gmbh Preparation comprising a creatine component, method for the production thereof, and the use thereof
US20150190410A1 (en) * 2012-07-16 2015-07-09 Dignity Health Use of creatine and phosphocreatine in the treatment of epilepsy and alcohol addiction

Also Published As

Publication number Publication date
DE102004038155A1 (de) 2006-03-16

Similar Documents

Publication Publication Date Title
AU2017253109B2 (en) Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans
DE69821123T2 (de) Diätzusammensetzung zur steigerung des metabolismus und zur linderung von oxydativem stress
KR100545630B1 (ko) 필수 지방산과 생물활성 이황화물을 함유하는 치료 및식이요법 조성물
WO2006015774A1 (fr) Composition physiologiquement acceptable contenant de l'acide alpha-lipoique, de la creatine et un phospholipide
EP1827413B1 (fr) Utilisation de complexes de cyclodextrines contenant de l'acide lipoique
DE60015893T2 (de) Zusammensetzung enthaltend ein carnitine und glutathion, zur erhöhung der absorption von glutathion und zur synergisierung seiner effekte
CA2344893C (fr) Combinaison de carnitines et de resveratrol pour prevenir ou traiter les troubles cerebraux ou du vieillissement
US20200129463A1 (en) Administration of butyrate, beta-hydroxybutyrate, cannabidiol, and related compounds in humans
DE102007030495A1 (de) Verwendung einer eine Kreatin-Komponente enthaltende Zusammensetzung zur Verbesserung der Gedächtnisleistung, der Merkfähigkeit, des Langzeitgedächtnisses und zur Vorbeugung geistiger Ermüdungszustände
US20040132821A1 (en) Therapeutic combination of carnitine and antioxidant polyphenols
DE10326822A1 (de) Mittel zur Nahrungsergänzung, dieses Mittel enthaltende pharmazeutische Präparate und Verwendungen des Mittels
JP2013544857A (ja) 皮膚疾患の治療のための局所使用のための組成物
EP2234506A1 (fr) Préparation comprenant un composant de créatine, procédé pour sa fabrication, et son utilisation
EP3461479B1 (fr) Compositions nutraceutiques et pharmaceutiques et leurs utilisations pour conserver les fonctions cognitives
EP1575593A2 (fr) Utilisation de derives de tetrahydrobiopterine pour traiter et alimenter des patients souffrant de troubles du metabolisme dus a un acide amine
JP2022538153A (ja) 生理的障害又は状態を治療又は予防するための、トリゴネリンを使用して細胞内ニコチンアミドアデニンジヌクレオチド（ｎａｄ＋）を産生する組成物及び方法
ITRM980433A1 (it) Composizione ad attivita' antiossidante antiproliferativa energetica e atta a migliorare l'utilizzazione metabolica del glucosio
WO2007073727A1 (fr) Nouvelles compositions pour lutter contre le alkyle-acyle gpc, des derives de celui-ci et des produits de celui-ci
WO2006042666A1 (fr) Utilisation d'acide alpha-lipoique r-(+) pour prevenir le diabete
US20130123355A1 (en) Fatty acids and metal ions compositions and uses thereof
AT412381B (de) Kombinations-präparat, enthaltend mineralstoffe, vitamine, kohlenhydrate und aminosäuren
US20230346723A1 (en) Administration of r-beta-hydroxybutyrate and related compounds in humans
DE102004035113A1 (de) alpha-Liponsäure enthaltende Zusammensetzung bei cystischer Fibrose
DE202008005023U1 (de) Verwendung von α-Liponsäure und Coenzym Q10 zur selektiven Reduktion des visceralen Fettgewebes
WO2023278881A1 (fr) Administration de r-bêta-hydroxybutyrate et de composés apparentés chez l'être humain

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase